Diagnostic accuracy of exhaled nitric oxide for the non-invasive identification of patients with fibrotic metabolic dysfunction-associated steatohepatitis.

ABSTRACT:

Background

Fibrotic metabolic dysfunction-associated steatohepatitis (MASH) is a condition at risk of progressing to advanced liver disease. We examined whether an innovative exhaled nitric oxide (eNO) breath test (BT) can accurately diagnose fibrotic MASH without requiring blood tests.

Methods

One hundred and forty-seven patients with MASH were recruited, and all tests were undertaken within 1 week of recruitment. With fibrotic MASH (NAS ≥ 4 and fibrosis stage ≥ 2) as the main outcome indicator, the diagnostic efficacy of eNO in identifying fibrotic MASH was compared to other validated models for advanced fibrosis requiring venesection, namely FAST, Agile 3⁺, and FIB-4 scores.

Results

The mean age was 40.36 ± 12.28 years, 73.5% were men. Mean body mass ind

SUBMITTER: Zhang H 

PROVIDER: S-EPMC11463020 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature